Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 10 Breast Neoplasms 9 Prostatic Neoplasms 7 Multiple Myeloma 6 Colorectal Neoplasms 5 Ovarian Neoplasms 4 Neoplasm Metastasis 4 Leukemia, Myeloid, Acute 4 Head and Neck Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Recurrence 3 Neoplasms, Plasma Cell 3 Lung Neoplasms 3 Hematologic Neoplasms 3 Glioblastoma 3 Carcinoma, Ovarian Epithelial 3 Urinary Bladder Neoplasms 2 Neoplasms by Site 2 Mycoses 2 Medication Adherence 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Follicular 2 Leukemia 2 Carcinoma, Transitional Cell 2 COVID-19 2 Adenocarcinoma 2 Uveal Melanoma 1 Urologic Neoplasms 1 Urologic Diseases 1 Urogenital Neoplasms 1

Interventions

Cannabidiol 5 Everolimus 2 enzalutamide 1 Temozolomide 1 Standard of Care 1 Solutions 1 Lenalidomide 1 Drug Therapy 1 2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Seizures × Standard of Care × Clear all

NCT04450160 2020-06-29

AEO

MetVital, Inc.

Phase 2 Unknown

Glioblastoma, Seizures

Data powered by HemOnc (CC BY 4.0) Colophon ⚡